MapLight Therapeutics, Inc. MPLT
7.07 USD -0.41 (-5.48%)
At closeNov 12, 2026, 4:01 PM EST
7.07 0.00 0.00%
After hours · Nov 12, 4:01 PM ET
7.01 Day range 7.64
6.06 52-week range 40.43
- YTD
- -59.76%
- 1 year
- -51.11%
News
globenewswire.com MapLight Therapeutics to Participate in Upcoming Investor Conference SAN FRANCISCO and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
benzinga.com Needham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43 Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $43.
benzinga.com MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement Financing MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders,…
benzinga.com UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13 UBS analyst Ashwani Verma downgrades MapLight Therapeutics (NASDAQ:MPLT) from Buy to Neutral and lowers the price target from $52 to $13.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's regular session. The market value of their outstanding shares is at $1.4 million. SciSparc (NASDAQ:SPRC)…- benzinga.com Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24 Canaccord Genuity analyst Sumant Kulkarni maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $24.
benzinga.com Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21 Morgan Stanley analyst Sean Laaman downgrades MapLight Therapeutics (NASDAQ:MPLT) from Overweight to Equal-Weight and lowers the price target from $34 to $21.
benzinga.com HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26 HC Wainwright & Co. analyst Raghuram Selvaraju maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $26.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved…
benzinga.com MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's pre-market session. The company's market cap stands at $1.5 million. Forte Biosciences (NASDAQ:FBRX)…
benzinga.com Maplight Therapeutics Says Phase 2 Zephyr Trial Of ML-007C-MA For Acute Exacerbation Of Schizophrenia Met Its Primary Endpoint, With 210/3 Mg Twice-Daily Dose, While 330/6 mg Once-daily Dose Missed Primary Endpoint The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to…- benzinga.com UBS Maintains Buy on MapLight Therapeutics, Raises Price Target to $52 UBS analyst Ashwani Verma maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $48 to $52.
benzinga.com BMO Capital Initiates Coverage On MapLight Therapeutics with Outperform Rating, Announces Price Target of $46 BMO Capital analyst Malcolm Hoffman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Outperform rating and announces Price Target of $46.
benzinga.com Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $45 Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $42 to $45.- benzinga.com Raymond James Initiates Coverage On MapLight Therapeutics with Strong Buy Rating, Announces Price Target of $46 Raymond James analyst Tiago Fauth initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Strong Buy rating and announces Price Target of $46.
- benzinga.com Craig-Hallum Maintains Buy on MapLight Therapeutics, Lowers Price Target to $40 Craig-Hallum analyst Adam Vogel maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $40.
- benzinga.com Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $42 Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $37 to $42.
benzinga.com MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.- benzinga.com MapLight Therapeutics Announces Topline Results From Its IRIS A Phase 2 Study Of ML-004 In Autism Spectrum Disorder; Trial Did Not Meet Its Primary Endpoint In Social Communication Deficits Associated With Autism Spectrum Disorder The study randomized 161 participants (102 adolescents, 59 adults), with prespecified analyses planned by age group and baseline irritability severity.As an exploratory signal-finding Phase 2 study,…
- benzinga.com Stifel Maintains Buy on MapLight Therapeutics, Raises Price Target to $36 Stifel analyst Paul Matteis maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $28 to $36.
- benzinga.com HC Wainwright & Co. Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MapLight Therapeutics (NASDAQ:MPLT) with a Buy and maintains $45 price target.
- benzinga.com UBS Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $48 UBS analyst Ashwani Verma initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $48.
- benzinga.com Craig-Hallum Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $43 Craig-Hallum analyst Adam Vogel initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $43.
- benzinga.com MapLight Therapeutics Q1 EPS $(1.34) Misses $(1.11) Estimate MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.11) by 20.72 percent. This is a 95.43 percent increase over…
benzinga.com This Prudential Financial Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See analyst ratings page for more info.
benzinga.com This First Tracks Biotherapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, including upgrades, downgrades, and initiations.
benzinga.com HC Wainwright & Co. Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $45 HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $45.
benzinga.com MapLight Therapeutics Completes Enrollment In Its Phase 2 Zephyr Trial Evaluating Ml-007C-MA For The Treatment Of Schizophrenia The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluating ML-004 for the treatment of autism spectrum disorder. The Company expects to report topline…
benzinga.com MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis, with key readouts expected through 2027.
benzinga.com This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrades and downgrades, on Benzinga's analyst ratings page.- benzinga.com 9 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Needham Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $37 Needham analyst Ami Fadia initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $37.
benzinga.com Earnings Scheduled For March 26, 2026 - benzinga.com MapLight Therapeutics Q4 EPS $(2.47) Misses $(0.96) Estimate MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(2.47) per share which missed the analyst consensus estimate of $(0.96) by 156.49 percent. This is a 91.16 percent increase over…
- benzinga.com Canaccord Genuity Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $35 Canaccord Genuity analyst Sumant Kulkarni initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $35.
- benzinga.com The FDA Has Granted Fast Track Designation To MapLight Therapeutics' ML-007C-MA For Hallucinations And Delusions Associated With Alzheimer's Disease Psychosis In a Phase 1 clinical trial, ML-007C-MA demonstrated a generally favorable safety and tolerability profile with twice daily dosing in healthy elderly participants. Enrollment is currently ongoing in…
- benzinga.com SandboxAQ And MapLight Therapeutics Collaborate To Discover And Develop Therapies Targeting G Protein-Coupled Receptor For Treatment Of Central Nervous System Disorders SandboxAQ and MapLight Therapeutics, Inc. (NASDAQ:MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies…
- benzinga.com MapLight Therapeutics Q3 EPS $(37.18) Misses $(1.55) Estimate MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(37.18) per share which missed the analyst consensus estimate of $(1.55) by 2291 percent. This is a 48.25 percent decrease over…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday - benzinga.com Jefferies Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $32 Jefferies analyst Andrew Tsai initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $32.
benzinga.com This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com Leerink Partners Initiates Coverage On MapLight Therapeutics with Outperform Rating, Announces Price Target of $30 Leerink Partners analyst Marc Goodman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Outperform rating and announces Price Target of $30.
- benzinga.com Stifel Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $28 Stifel analyst Paul Matteis initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $28.
- benzinga.com Morgan Stanley Initiates Coverage On MapLight Therapeutics with Overweight Rating, Announces Price Target of $34 Morgan Stanley analyst Sean Laaman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Overweight rating and announces Price Target of $34.